DENTSPLY SIRONA Inc. (XRAY) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: strong product sales and EMEA growth, but weak guidance and margin contraction. The restructuring plan shows potential, but its benefits are long-term. Eliminating dividends for debt reduction and share repurchases is neutral. Unclear management responses in Q&A raise concerns. These factors balance out, suggesting a neutral stock price movement in the short term.
Key Financial Performance
Revenue $880 million, representing an as-reported sales increase of 0.1% over the prior quarter. On a constant currency basis, sales declined 6.7% due to the impact from Byte and a strong Q1 2025 treatment center sales not repeated in 2026. Adjusting for these one-time headwinds, Q1 2026 sales on a constant currency basis were down 4.5%.
Adjusted EBITDA margins Declined 430 basis points, resulting from a 560 basis points decline in gross profit, driven by lower volumes, sales mix, and tariff impacts.
Operating cash flow $40 million compared to $7 million in the prior year quarter. The year-over-year increase is primarily attributable to improvements in working capital with lower accounts receivable.
Cash and cash equivalents $190 million at the end of the quarter.
Net debt-to-EBITDA ratio 3.3x during the quarter.
Debt reduction $79 million of debt retired during the quarter.
CTS segment constant currency sales Declined 2.9%. High single-digit decline in E&I due to declines in imaging equipment and treatment centers driven by a tougher comp versus the prior year quarter. Adjusting for the one-time institutional installation, CTS was flat in constant currency.
Global CAD/CAM business Flat year-over-year with growth in APAC offset by a decline in EMEA, driven by softness in the Middle East and Central Europe, partially offset by double-digit growth in U.K., Spain, Turkey, and Denmark.
EDS constant currency sales Declined 7.2%, driven by lower volumes in Americas and EMEA, partially offset by growth across all three product categories in APAC.
OIS constant currency sales Declined 13.5%. Adjusting for year-over-year impact from Byte, OIS declined 7.6%. IPS declined high single digits due to lower implant volume across all three regions. SureSmile declined low single digits with a high single-digit decline in the U.S., partially offset by 11% growth in EMEA.
Wellspect Healthcare constant currency sales Increased 3.4%, led by 4% growth in EMEA and the continued strength of new product sales and execution of the business.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Smart View-Detect: Launched as the first FDA-cleared and CE-marked AI-enabled diagnostic aid for identifying potential inflammation at the root tip in 3D scans. It integrates into the DS core platform and improves detection sensitivity by 46%.
Reciproc Minima file system and X-Smart Go cordless endo motor: Introduced to simplify workflows and improve efficiency in endodontics. Reciproc Minima treats narrow and complex canals with a one-file approach, while X-Smart Go enhances mobility and performance.
Dental dedicated MRI: Received FDA clearance, expanding capabilities in soft tissue diagnostics and supporting collaboration with academic and research institutions.
Surety for males: Launched as an extension of the Surety portfolio, targeting a broader patient population with ease-of-use and patient comfort.
U.S. distribution network expansion: Signed an expanded agreement with Atlanta Dental Supply, marking the fourth new distributor agreement this year. This enhances regional coverage and access to connected technology solutions.
Restructuring program: On track to deliver $120 million in annual savings through cost optimization, organizational simplification, and supply chain efficiencies. Approximately $20 million in operating expenses were reduced in Q1.
AI-enabled tools: Deployed in select workflows to improve productivity, with broader rollout planned throughout the year.
Return-to-Growth action plan: Focused on disciplined execution, lean operating principles, and embedding customer-centric processes. Early proof points include improved working capital and reduced operating expenses.
R&D investment: Increased spending to support innovation and bring high-value opportunities to market.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geopolitical and macroeconomic factors: The company is monitoring geopolitical and macroeconomic factors closely, which could impact market conditions and overall performance.
Decline in sales and revenue: Sales declined 6.7% on a constant currency basis, with specific declines in EDS, CTS, and OIS segments. Lower volumes, sales mix, and tariff impacts contributed to a 560 basis points decline in gross profit.
Challenges in U.S. distributor levels: U.S. distributor levels for CAD/CAM and imaging products remain below historical averages, a trend expected to continue.
Implant business performance: The implant business has faced challenges with lower implant volumes across all regions.
Restructuring and cost optimization risks: The company is undergoing restructuring to achieve $120 million in annual savings, which involves cost optimization, organizational simplification, and supply chain efficiencies. These changes carry execution risks.
Debt and financial management: The company has a net debt-to-EBITDA ratio of 3.3x and is prioritizing debt reduction. However, financial management remains critical to maintaining investment-grade credit metrics.
Regulatory and compliance risks: The company is introducing new products like AI-enabled diagnostic tools and dental MRI systems, which require regulatory clearances and compliance, posing potential risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Financial Outlook: The company is maintaining its 2026 outlook for net sales of $3.5 billion to $3.6 billion and an adjusted EPS in the range of $1.40 to $1.50.
Revenue and Market Trends: U.S. distributor levels for CAD/CAM and imaging products are expected to remain below historical averages. The company is applying a risk-aware approach to guidance due to macro and geopolitical uncertainties.
Cost Optimization and Restructuring: The restructuring program is on track to deliver approximately $120 million in annual savings, with benefits becoming more meaningful in the second half of 2026. Savings will be reinvested into growth areas such as R&D, clinical education, and commercial capabilities.
Debt Reduction and Capital Allocation: The company reduced debt by approximately $80 million in Q1 and plans to prioritize debt reduction and share repurchases. The dividend elimination provides increased flexibility for capital deployment.
Innovation and Product Launches: Recent launches include Smart View-Detect, Reciproc Minima file system, X-Smart Go cordless endo motor, and a dental-dedicated MRI. These innovations aim to enhance diagnostic confidence, simplify workflows, and expand capabilities.
U.S. Market Growth: Returning the U.S. to growth is a top priority. Actions include strengthening talent, expanding distribution, and improving customer engagement. Early traction is visible with new distributor agreements and increased commercial reach.
AI and Operational Efficiency: The company is advancing its enterprise AI strategy to drive efficiency and support innovation. AI-enabled tools are being deployed in select workflows, with broader rollout planned throughout the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend elimination: The dividend was eliminated during the first quarter to increase flexibility in capital deployment.
Share repurchases: Capital allocation priorities include share repurchases, with the timing to be evaluated later this year as performance improves.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the timing of benefits from the Return-to-Growth action plan?
A:The Return-to-Growth plan is a 24-month plan. Initial restructuring benefits are expected in the fourth quarter of this year, with more significant improvements anticipated in 2027 and 2028.
Q:What is the update on early conversations with DSOs?
A:There is significant interest in the broad portfolio offered, including building new dental suites and consumables. Active plans are expected to materialize more in the second half of this year and into next year.
Q:Are there any notable trends across regions (Americas, EMEA, APAC)?
A:The Middle East has a small impact, while Central Europe continues to struggle due to geopolitical issues. The U.S. is performing as expected, and APAC is showing strength due to strong leadership and execution.
Q:What is the status of the drop ship model with distributors?
A:The transition applies to existing dealers, with inventory burn expected from Q2 through Q4. The model is well-received and built into agreements, but Q4 guidance is not provided yet.
Q:What caused the decline in EDS performance?
A:The decline is attributed to specific markets, particularly in Europe, and dealer destocking. The company believes this is a timing issue and expects recovery.
Q:What is the outlook for Europe in the Return-to-Growth plan?
A:Europe is expected to return to growth, with a focus on addressing specific market challenges and leveraging the U.S. growth strategies globally.
Q:What drove the 550 basis points contraction in gross margin in Q1?
A:The contraction was driven by tariffs, negative mix from EDS performance, and volume absorption issues. Improvements are expected in Q2 and Q3.
Q:What is the impact of macro and geopolitical factors on input costs?
A:There are some headwinds from higher oil and freight prices, but the company is monitoring and assessing potential actions. No material impact has been disclosed yet.
Q:What is the strategy for addressing the shift towards private label consumables?
A:The company is developing programs to compete effectively against private label products and penetrate the market creatively.
Q:What is the contribution of new products to growth?
A:Specific contributions are not disclosed, but new products are expected to ramp up contributions over the year and into 2027 and 2028.
Q:What is the strategy for implants in the Return-to-Growth plan?
A:The focus is on improving execution, clinical education, and rep training. The company is working on holistic programs to address underperformance in implants.
Q:What is the approach to capital deployment and share buybacks?
A:The company is prioritizing debt reduction in the first half of the year and plans to evaluate share buybacks in the second half, depending on financial performance.
Q:Why was guidance not updated despite a Q1 beat?
A:The CEO prefers to wait for at least two quarters of performance before updating guidance, reflecting a conservative approach.
Q:What drove the strength in CTS performance?
A:The strength is attributed to activities in the U.S. through dealer partnerships.
Q:What is the outlook for M&A and portfolio rationalization?
A:The company is not actively pursuing M&A but is staying current with potential opportunities. Portfolio rationalization will be evaluated after stabilizing and growing the business.
Q:What is the competitive landscape for intraoral scanners (iOS)?
A:New low-cost entrants are impacting the market. The company plans to address this with bundled strategies leveraging its broad portfolio.
Q:What are the key innovation areas highlighted?
A:Key areas include AI detection for DS Core, Wellspect's Surety launch, Reciproc Minima for endodontics, and MRI technology for long-term clinical applications.
Q:What is the impact of input costs on guidance?
A:No material impact has been disclosed, but the company is reserving the right to update guidance if unforeseen changes occur.
Q:What is the strategy for addressing lower implant volumes?
A:The company plans to reposition its value brand (MIS) and improve execution and education for its premium brand (Astra).
Q:What is the status of the inventory sell-through under the new drop ship model?
A:No impact was realized in Q1. The $30 million headwind is expected to occur in late Q2 and the second half of the year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for Q4 EBITDA margins, detailed contributions of new products to growth, and specific strategies for addressing private label competition. Additionally, they refrained from disclosing details about certain market challenges and competitive programs for implants.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APAC CTS
APAC OIS
APAC SureSmile
APAC decline
APAC distributor
APAC update
Americas EMEA
Byte treatment
CAM APAC
CTS currency
Central Europe
DENTSPLY SIRONA
Denmark demand
EDS APAC
EDS product
EMEA Wellspect
Financial Officer
Interim
Return action
Sales currency
action plan
afternoon
basis currency
basis sale
control
currency sale
decline EMEA
digit decline
improvement
increase
investment
perspective
reporting
restructuring
sale digit
stage plan
today change
treatment center
XRAY Transcript
DENTSPLY SIRONA Inc. (XRAY) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call reveals mixed signals: strong product sales and EMEA growth, but weak guidance and margin contraction. The restructuring plan shows potential, but its benefits are long-term. Eliminating dividends for debt reduction and share repurchases is neutral. Unclear management responses in Q&A raise concerns. These factors balance out, suggesting a neutral stock price movement in the short term.
DENTSPLY SIRONA Inc. (XRAY) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
DENTSPLY SIRONA Inc. (XRAY) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call summary presents a mixed outlook: while there are positive elements such as strategic investments, operational improvements, and a favorable agreement with Patterson, there are also concerns about declining sales and unclear management responses on key issues like free cash flow and new product launches. The Q&A section reveals optimism for future growth but also highlights uncertainties, particularly with regulatory approvals and market penetration strategies. Given the absence of a market cap, the predicted stock movement is neutral, reflecting both potential growth and existing challenges.
DENTSPLY SIRONA Inc. (XRAY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
XRAY Slides
Dentsply Sirona Q4 2025 slides: revenue beats amid restructuring push2026-02-26
Dentsply Sirona Q3 2025 slides: Sales decline despite margin gains, stock falls 12%2025-11-06
Dentsply Sirona Q2 2025 slides: Sales decline offset by margin expansion under new leadership2025-08-07
Dentsply Sirona Q1 2025 slides: Margin expansion offsets continued sales decline2025-05-08
XRAY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
